Deprecated: Non-canonical cast (double) is deprecated, use the (float) cast instead in /home/clients/36e828465228e0d5d4e8c936b1cff976/sites/cemka.fr/wp-content/plugins/wordfence/vendor/wordfence/wf-waf/src/lib/xmlrpc.php on line 216

Deprecated: Non-canonical cast (boolean) is deprecated, use the (bool) cast instead in /home/clients/36e828465228e0d5d4e8c936b1cff976/sites/cemka.fr/wp-content/plugins/wordfence/vendor/wordfence/wf-waf/src/lib/xmlrpc.php on line 235
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. - cemka

.sf-swipe-indicator{--wpr-bg-5dd6c5fe-5e24-4bce-999a-ae4f5260dc3d: url('https://www.cemka.fr/wp-content/themes/dante/images/swipe_indicator.png');}.sf-swipe-indicator{--wpr-bg-817740d9-bc30-4273-8115-391c3d0c023f: url('https://www.cemka.fr/wp-content/themes/dante/images/swipe_indicator@2x.png');}.ilightbox-loader.metro-white div{--wpr-bg-9ad21062-8750-42a1-93bd-ddaf5526c631: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/preloader.gif');}.ilightbox-holder.metro-white .ilightbox-container .ilightbox-caption{--wpr-bg-64b5a885-296d-494d-9cec-5e5bb8c43828: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/caption-bg.png');}.ilightbox-holder.metro-white .ilightbox-alert{--wpr-bg-39c2b03e-eec8-40e4-9e76-09ad8512993a: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/alert.png');}.ilightbox-toolbar.metro-white a{--wpr-bg-8064e3fe-0b41-405d-b189-23378efca468: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/buttons.png');}.ilightbox-thumbnails.metro-white .ilightbox-thumbnails-grid .ilightbox-thumbnail .ilightbox-thumbnail-video{--wpr-bg-f01e5c47-54b8-4b23-9181-c6a5bece6c4e: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/thumb-overlay-play.png');}.ilightbox-loader.metro-black div{--wpr-bg-91e9ef96-a256-4841-b7f7-ade8c0aa216c: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/preloader.gif');}.ilightbox-holder.metro-black .ilightbox-container .ilightbox-caption{--wpr-bg-2bb8e25e-b814-491f-9da4-681d872716e8: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/caption-bg.png');}.ilightbox-holder.metro-black .ilightbox-alert{--wpr-bg-406ce3cf-7352-459f-b21d-0181515b9419: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/alert.png');}.ilightbox-toolbar.metro-black a{--wpr-bg-b015e7bf-297c-4289-b0c5-f01e0d45f656: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/buttons.png');}.ilightbox-thumbnails.metro-black .ilightbox-thumbnails-grid .ilightbox-thumbnail .ilightbox-thumbnail-video{--wpr-bg-e6162b83-3c50-4f04-b330-aec0dc6ac589: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/thumb-overlay-play.png');}.carousel-wrap a.carousel-next,.carousel-wrap a.carousel-prev{--wpr-bg-7c087581-6359-4456-8e6e-0f415fa862f6: url('https://www.cemka.fr/wp-content/themes/dante/images/showcase-nav.png');}.carousel-wrap a.carousel-next,.carousel-wrap a.carousel-prev{--wpr-bg-6415c3df-f236-4320-813b-57d6ce80f620: url('https://www.cemka.fr/wp-content/themes/dante/images/showcase-nav2.png');}.carousel-wrap a.carousel-next,.carousel-wrap a.carousel-prev{--wpr-bg-3e564332-f704-428d-b1ee-4aaa8f020a2c: url('https://www.cemka.fr/wp-content/themes/dante/images/showcase-nav@2x.png');}.ajax-search-wrap .ajax-loading{--wpr-bg-906d50ed-4723-4369-92c9-b55b3adb17f8: url('https://www.cemka.fr/wp-content/themes/dante/images/loader.gif');}#swift-slider .swift-slider-loading{--wpr-bg-c86990cc-0fbb-45fc-bf0b-e2a0b955672f: url('https://www.cemka.fr/wp-content/themes/dante/images/loader.gif');}.owl-carousel .owl-video-play-icon{--wpr-bg-606523a7-6f2b-43ca-9b88-a2eda1ef95f9: url('https://www.cemka.fr/wp-content/themes/dante/css/owl.video.play.png');}.header-right #lang_sel a.lang_sel_sel{--wpr-bg-8d313eea-7656-45d8-a691-760f03f7affc: url('https://www.cemka.fr/wp-content/themes/dante/images/language-arrow.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-fullscreen{--wpr-bg-d29e0a10-64d4-4936-a6e1-8a3a35151a99: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/fullscreen-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-fullscreen:hover{--wpr-bg-c8f25af9-ab61-4712-a154-30d39c75fa0b: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/fullscreen-hover-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-next-button{--wpr-bg-460e7c1d-ff67-4315-928e-bdac11546816: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/arrow-next-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-next-button:hover{--wpr-bg-0f144c90-335b-459f-b3e2-b1a51010ab00: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/arrow-next-hover-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-next-button.disabled{--wpr-bg-d34f683d-b03c-4011-b955-86234e52841e: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/arrow-next-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-prev-button{--wpr-bg-b60ef29e-a5af-46d1-af12-c73bb1ea1663: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/arrow-prev-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-prev-button:hover{--wpr-bg-ddb92ef0-44bd-4bc2-9e1a-42b7f8358bd1: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/arrow-prev-hover-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-prev-button.disabled{--wpr-bg-f56dfa01-3ea2-48cd-b034-6d2b12abab9b: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/arrow-prev-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-play{--wpr-bg-bb67f00b-ff03-46c6-90f5-fb0cc1eca5bd: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/play-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-play:hover{--wpr-bg-7db6023a-af83-45c3-ba39-2f7ec6895077: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/play-hover-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-pause{--wpr-bg-30666c0b-3c31-4306-8054-d56b2a92fc8b: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/pause-icon-64.png');}.isMobile .ilightbox-toolbar.metro-white a.ilightbox-pause:hover{--wpr-bg-2dfa885d-9788-42f8-80a1-4be3b30426ab: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-light/pause-hover-icon-64.png');}.isMobile .ilightbox-toolbar.metro-black a.ilightbox-fullscreen{--wpr-bg-573885a6-439c-47dd-b6fc-cd48ec99305a: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/fullscreen-icon-64.png');}.isMobile .ilightbox-toolbar.metro-black a.ilightbox-next-button{--wpr-bg-bbe1ccd2-9744-44a6-bcd5-56835597d6ea: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/arrow-next-icon-64.png');}.isMobile .ilightbox-toolbar.metro-black a.ilightbox-prev-button{--wpr-bg-ab10487f-5b39-4c2e-bf3f-a2b24b11b377: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/arrow-prev-icon-64.png');}.isMobile .ilightbox-toolbar.metro-black a.ilightbox-play{--wpr-bg-a6250d19-7d1f-4735-953d-2b40f0905c00: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/play-icon-64.png');}.isMobile .ilightbox-toolbar.metro-black a.ilightbox-pause{--wpr-bg-a48c7a47-c11a-4b32-b297-4cb4bc44ca0e: url('https://www.cemka.fr/wp-content/themes/dante/images/lightbox/metro-dark/pause-icon-64.png');}.page-heading{--wpr-bg-36a015e3-1bb5-490b-a5eb-c7bc1b516b14: url('https://www.cemka.fr/wp-content/themes/dante/images/bg-heading-new.jpg');}.rll-youtube-player .play{--wpr-bg-c86c1efa-5c26-4aa1-b88e-a4b025487e03: url('https://www.cemka.fr/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

19.07.2016

M LLIBRE J, RAFFI F, MOYLE G, BEHRENS G, BOUEE S, REILLY G, BORG P, PIONTKOWSKY D, ROGATTO F.

Posté par Marianne Giampiccolo, le 19.07.2016

Classé dans :

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

Sitemap

CONTACT

Suivez-nous

Rejoignez-nous